Given the enormous estimated burden of respiratory virus infections worldwide, a substantial number of research priorities exist in order to better understand their epidemiology, pathogenesis, prevention and clinical management across different populations and resource settings. New therapeutics and specific vaccines for noninfluenza respiratory virus infections could provide enormous benefits in reducing the morbidity and mortality associated with these frequent infections and provide the foundation for responding to newly emerging threats. The BRaVe Initiative is a new WHO-led effort to catalyze multidisciplinary research on strategies to prevent and treat medically important respiratory virus infections with the goal of timely integration of scientific advances and technical innovations into public health practice.

Keywords:

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

1 Liu L, Johnson HL, Cousens S et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet379(9832),2151–2161 (2012).▪ Overview of childhood mortality trends over the past decade indicating the current public health priorities to address and the contributions of pneumonia and respiratory infections.
MedlineGoogle Scholar
2 Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. Lancet377(9773),1264–1275 (2011).▪ Rigorous review that examines the role of respiratory viruses in community-acquired pneumonia in adults and children.
MedlineGoogle Scholar
3 Nair H, Simoes EA, Rudan I et al. Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis. Lancet381(9875),1380–1390 (2013).▪ Recent study on the global burden of ALRI in children and its impacts on individuals and healthcare systems.
MedlineGoogle Scholar
4 Gern JE. The ABCs of rhinoviruses, wheezing, and asthma. J. Virol.84(15),7418–7426 (2010).
Medline CASGoogle Scholar
5 Madhi SA, Klugman KP. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat. Med.10(8),811–813 (2004).
Medline CASGoogle Scholar
6 Casscells SW, Granger E, Kress AM, Linton A, Madjid M, Cottrell L. Use of oseltamivir after influenza infection is associated with reduced incidence of recurrent adverse cardiovascular outcomes among military health system beneficiaries with prior cardiovascular diseases. Circ. Cardiovasc. Qual. Outcomes2(2),108–115 (2009).
MedlineGoogle Scholar
7 Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med.352(17),1749–1759 (2005).
Medline CASGoogle Scholar
8 Madjid M, Curkendall S, Blumentals WA. The influence of oseltamivir treatment on the risk of stroke after influenza infection. Cardiology113(2),98–107 (2009).
Medline CASGoogle Scholar
9 van AL, van den Wijngaard C, van PW et al. Mortality attributable to 9 common infections: significant effect of influenza A, respiratory syncytial virus, influenza B, norovirus, and parainfluenza in elderly persons. J. Infect. Dis.206(5),628–639 (2012).
MedlineGoogle Scholar
10 Warren-Gash C, Bhaskaran K, Hayward A et al. Circulating influenza virus, climatic factors, and acute myocardial infarction: a time series study in England and Wales and Hong Kong. J. Infect. Dis.203(12),1710–1718 (2011).
MedlineGoogle Scholar
11 Zhu T, Carcaillon L, Martinez I et al. Association of influenza vaccination with reduced risk of venous thromboembolism. Thromb. Haemost.102(6),1259–1264 (2009).
Medline CASGoogle Scholar
12 Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax67(1),71–79 (2012).
Medline CASGoogle Scholar
13 Molinari NA, Ortega-Sanchez IR, Messonnier ML et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine25(27),5086–5096 (2007).
MedlineGoogle Scholar
14 Fendrick AM, Monto AS, Nightengale B, Sarnes M. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch. Intern. Med.163(4),487–494 (2003).
MedlineGoogle Scholar
15 Anderson LJ, Baric RS. Emerging human coronaviruses – disease potential and preparedness. N. Engl. J. Med.367(19),1850–1852 (2012).
Medline CASGoogle Scholar
16 Gao R, Cao B, Hu Y et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N. Engl. J. Med.368(20),1888–1897 (2013).
Medline CASGoogle Scholar
17 Uyeki TM, Cox NJ. Global concerns regarding novel influenza A (H7N9) virus infections. N. Engl. J. Med.368(20),1862–1864 (2013).
Medline CASGoogle Scholar
18 Zaki AM, van BS, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med.367(19),1814–1820 (2012).
Medline CASGoogle Scholar
19 Lee JW, McKibbin WJ. Estimating the global economic costs of SARS. In: Learning from SARS: Preparing for the Next Disease Outbreak: Workshop Summary. Knobler S. Seale MAL (Eds). Institute of Medicine (US) Forum on Microbial Threats, National Academies Press, DC, USA (2004).
Google Scholar
20 Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect. Dis.12(1),36–44 (2012).
MedlineGoogle Scholar
21 Girard MP, Tam JS, Pervikov Y, Katz JM. Report on the first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Hong Kong SAR, China, 24–26 January 2013. Vaccine31(37),3766–3771 (2013).
MedlineGoogle Scholar
22 Cheng Y, Wong R, Soo YO et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur. J. Clin. Microbiol. Infect. Dis.24(1),44–46 (2005).
Medline CASGoogle Scholar
23 Hung IF, To KK, Lee CK et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin. Infect. Dis.52(4),447–456 (2011).
MedlineGoogle Scholar
24 Hung IF, To KK, Lee CK et al. Hyperimmune intravenous immunoglobulin treatment: a multicentre double-blind randomized controlled trial for patients with severe A(H1N1)pdm09 infection. Chest144(2),464–473 (2013).▪ Up-to-date summary of developments in influenza vaccinology including the prospects for developing vaccines that elicit broadly protective and long-lasting immune responses.
MedlineGoogle Scholar
25 Hernan MA, Lipsitch M. Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clin. Infect. Dis.53(3),277–279 (2011).
Medline CASGoogle Scholar
26 Chan MC, Lee N, Lui GC et al. Comparisons of oseltamivir-resistant (H275Y) and concurrent oseltamivir-susceptible seasonal influenza A(H1N1) virus infections in hospitalized adults, 2008–2009. Influenza Other Respi. Viruses7(3),235–239 (2013).
MedlineGoogle Scholar
27 Louie JK, Yang S, Acosta M et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin. Infect. Dis.55(9),1198–1204 (2012).
Medline CASGoogle Scholar
28 Muthuri SG, Myles PR, Venkatesan S, Leonardi-Bee J, Nguyen-Van-Tam JS. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009–2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. J. Infect. Dis.207(4),553–563 (2013).
Medline CASGoogle Scholar
29 Yang SG, Cao B, Liang LR et al. Antiviral therapy and outcomes of patients with pneumonia caused by influenza A pandemic (H1N1) virus. PLoS ONE7(1),e29652 (2012).
Medline CASGoogle Scholar
30 Hayden FG. Newer influenza antivirals, biotherapeutics and combinations. Influenza Other Respi. Viruses7(Suppl. 1),63–75 (2013).▪ Overview of current and investigational antivirals and other therapeutics for influenza treatment.
MedlineGoogle Scholar
31 Hughes B, Hayden F, Perikov Y, Hombach J, Tam JS. Report of the 5th meeting on influenza vaccines that induce broad spectrum and long-lasting immune responses. World Health Organization, Geneva, 16–17 November 2011. Vaccine30(47),6612–6622 (2012).
MedlineGoogle Scholar
32 Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA289(2),179–186 (2003).
MedlineGoogle Scholar
33 Kouni S, Karakitsos P, Chranioti A, Theodoridou M, Chrousos G, Michos A. Evaluation of viral co-infections in hospitalized and non-hospitalized children with respiratory infections using microarrays. Clin. Microbiol. Infect.19(8),772–777 (2012).
MedlineGoogle Scholar
34 McCullers JA, Bartmess KC. Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae. J. Infect. Dis.187(6),1000–1009 (2003).
Medline CASGoogle Scholar
35 Heinonen S, Silvennoinen H, Lehtinen P et al. Early oseltamivir treatment of influenza in children 1–3 years of age: a randomized controlled trial. Clin. Infect. Dis.51(8),887–894 (2010).
Medline CASGoogle Scholar
36 Whitley RJ, Hayden FG, Reisinger KS et al. Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J.20(2),127–133 (2001).
Medline CASGoogle Scholar
37 de Chassey B, Meyniel-Schicklin L, Aublin-Gex A, Andre P, Lotteau V. Genetic screens for the control of influenza virus replication: from meta-analysis to drug discovery. Mol. Biosyst.8(4),1297–1303 (2012).
Medline CASGoogle Scholar
38 Ludwig S. Disruption of virus–host cell interactions and cell signaling pathways as an anti-viral approach against influenza virus infections. Biol. Chem.392(10),837–847 (2011).
Medline CASGoogle Scholar
39 Stertz S, Shaw ML. Uncovering the global host cell requirements for influenza virus replication via RNAi screening. Microbes. Infect.13(5),516–525 (2011).
Medline CASGoogle Scholar
40 Smith SB, Dampier W, Tozeren A, Brown JR, Magid-Slav M. Identification of common biological pathways and drug targets across multiple respiratory viruses based on human host gene expression analysis. PLoS ONE7(3),e33174 (2012).
Medline CASGoogle Scholar
41 Jagger BW, Wise HM, Kash JC et al. An overlapping protein-coding region in influenza A virus segment 3 modulates the host response. Science337(6091),199–204 (2012).
Medline CASGoogle Scholar
42 Bezerra PG, Britto MC, Correia JB et al. Viral and atypical bacterial detection in acute respiratory infection in children under five years. PLoS ONE6(4),e18928 (2011).
Medline CASGoogle Scholar
43 Mermond S, Zurawski V, D’Ortenzio E et al. Lower respiratory infections among hospitalized children in New Caledonia: a pilot study for the Pneumonia Etiology Research for Child Health project. Clin. Infect. Dis.54(Suppl. 2),S180–S189 (2012).
Medline CASGoogle Scholar
44 Winther B, Hayden FG, Hendley JO. Picornavirus infections in children diagnosed by RT-PCR during longitudinal surveillance with weekly sampling: association with symptomatic illness and effect of season. J. Med. Virol.78(5),644–650 (2006).
MedlineGoogle Scholar
45 de Jong MD, Simmons CP, Thanh TT et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med.12(10),1203–1207 (2006).
Medline CASGoogle Scholar
46 Everitt AR, Clare S, Pertel T et al. IFITM3 restricts the morbidity and mortality associated with influenza. Nature484(7395),519–523 (2012).
Medline CASGoogle Scholar
47 Zhang YH, Zhao Y, Li N et al. Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with severe influenza in Chinese individuals. Nat. Commun.4,1418 (2013).
MedlineGoogle Scholar
48 Sugaya N, Kohno S, Ishibashi T, Wajima T, Takahashi T. Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection. Antimicrob. Agents Chemother.56(1),369–377 (2012).
Medline CASGoogle Scholar
49 Yamada T, Yamada T, Morikawa M et al. Pandemic (H1N1) 2009 in pregnant Japanese women in Hokkaido. J. Obstet. Gynaecol. Res.38(1),130–136 (2012).
MedlineGoogle Scholar
50 Dubar G, Azria E, Tesniere A et al. French experience of 2009 A/H1N1v influenza in pregnant women. PLoS ONE5(10),pii: e13112 (2010).
Google Scholar
51 Lee N, Chan PK, Wong CK et al. Viral clearance and inflammatory response patterns in adults hospitalized for pandemic 2009 influenza A(H1N1) virus pneumonia. Antivir. Ther.16(2),237–247 (2011).
MedlineGoogle Scholar
52 Li IW, Hung IF, To KK et al. The natural viral load profile of patients with pandemic 2009 influenza A(H1N1) and the effect of oseltamivir treatment. Chest137(4),759–768 (2010).
Medline CASGoogle Scholar
53 Miller PE, Rambachan A, Hubbard RJ et al. Supply of neuraminidase inhibitors related to reduced influenza A (H1N1) mortality during the 2009–2010 H1N1 pandemic: an ecological study. PLoS ONE7(9),e43491 (2012).
Medline CASGoogle Scholar
54 Nukiwa N, Kamigaki T, Oshitani H. Fatal cases of pandemic (H1N1) 2009 influenza despite their early antiviral treatment in Japan. Clin. Infect. Dis.51(8),993–994 (2010).
MedlineGoogle Scholar
55 Hu Y, Lu S, Song Z et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet381(9885),2273–2279 (2013).
MedlineGoogle Scholar
56 Geevarghese B, Simoes EA. Antibodies for prevention and treatment of respiratory syncytial virus infections in children. Antivir. Ther.17(1 Pt B),201–211 (2012).
Medline CASGoogle Scholar
57 DeVincenzo JP. The promise, pitfalls and progress of RNA-interference-based antiviral therapy for respiratory viruses. Antivir. Ther.17(1 Pt B),213–225 (2012).▪ Extensive review on RNAi-based therapeutics and their application as antivirals for respiratory virus infections.
Medline CASGoogle Scholar
58 Chen YB, Driscoll JP, McAfee SL et al. Treatment of parainfluenza 3 infection with DAS181 in a patient after allogeneic stem cell transplantation. Clin. Infect. Dis.53(7),e77–e80 (2011).
MedlineGoogle Scholar
59 Florescu DF, Pergam SA, Neely MN et al. Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. Biol. Blood Marrow Transplant.18(5),731–738 (2012).
Medline CASGoogle Scholar
60 Shaw ML. The host interactome of influenza virus presents new potential targets for antiviral drugs. Rev. Med. Virol.21(6),358–369 (2011).
Medline CASGoogle Scholar
61 Agrati C, Gioia C, Lalle E et al. Association of profoundly impaired immune competence in H1N1v-infected patients with a severe or fatal clinical course. J. Infect. Dis.202(5),681–689 (2010).
MedlineGoogle Scholar
62 Camargo CA Jr, Ganmaa D, Frazier AL et al. Randomized trial of vitamin D supplementation and risk of acute respiratory infection in Mongolia. Pediatrics130(3),e561–e567 (2012).
MedlineGoogle Scholar
63 Murdoch DR, Slow S, Chambers ST et al. Effect of vitamin D3 supplementation on upper respiratory tract infections in healthy adults: the VIDARIS randomized controlled trial. JAMA308(13),1333–1339 (2012).
Medline CASGoogle Scholar
64 Roth DE, Caulfield LE, Ezzati M, Black RE. Acute lower respiratory infections in childhood: opportunities for reducing the global burden through nutritional interventions. Bull. World Health Organ.86(5),356–364 (2008).
MedlineGoogle Scholar
65 Scott JA, Brooks WA, Peiris JS, Holtzman D, Mulholland EK. Pneumonia research to reduce childhood mortality in the developing world. J. Clin. Invest118(4),1291–1300 (2008).
Medline CASGoogle Scholar
66 Singh M, Das RR. Zinc for the common cold. Cochrane Database Syst. Rev.2,CD001364 (2011).
MedlineGoogle Scholar
67 Popova M, Molimard P, Courau S et al. Beneficial effects of probiotics in upper respiratory tract infections and their mechanical actions to antagonize pathogens. J. Appl. Microbiol.113(6),1305–1318 (2012).
Medline CASGoogle Scholar
68 Fedson DS. Treating influenza with statins and other immunomodulatory agents. Antiviral Res. doi:10.1016/j.antiviral.2013.06.018 (2013) (Epub ahead of print).
MedlineGoogle Scholar
69 Shillcutt S, Morel C, Goodman C et al. Cost–effectiveness of malaria diagnostic methods in sub-Saharan Africa in an era of combination therapy. Bull. World Health Organ.86(2),101–110 (2008).
MedlineGoogle Scholar
70 Thiam S, Thior M, Faye B et al. Major reduction in anti-malarial drug consumption in Senegal after nation-wide introduction of malaria rapid diagnostic tests. PLoS ONE6(4),e18419 (2011).
Medline CASGoogle Scholar
71 Gilbert DN. Procalcitonin as a biomarker in respiratory tract infection. Clin. Infect. Dis.52(Suppl. 4),S346–S350 (2011).
Medline CASGoogle Scholar
72 Zimmerman O, Rogowski O, Aviram G et al. C-reactive protein serum levels as an early predictor of outcome in patients with pandemic H1N1 influenza A virus infection. BMC Infect. Dis.10,288 (2010).
MedlineGoogle Scholar
73 Vernet G, Saha S, Satzke C et al. Laboratory-based diagnosis of pneumococcal pneumonia: state of the art and unmet needs. Clin. Microbiol. Infect.17(Suppl. 3),1–13 (2011).
MedlineGoogle Scholar
74 Belle J, Cohen H, Shindo N et al. Influenza preparedness in low-resource settings: a look at oxygen delivery in 12 African countries. J. Infect. Dev. Ctries4(7),419–424 (2010).▪ Insightful country-specific picture on capacity and equipment to deliver oxygen therapy that highlights the difficulty of implementing a simple life-saving intervention in resource-limited settings.
MedlineGoogle Scholar
75 Kronman MP, Zaoutis TE, Haynes K, Feng R, Coffin SE. Antibiotic exposure and IBD development among children: a population-based cohort study. Pediatrics130(4),e794–e803 (2012).
MedlineGoogle Scholar
76 Trasande L, Blustein J, Liu M, Corwin E, Cox LM, Blaser MJ. Infant antibiotic exposures and early-life body mass. Int. J. Obes. (Lond.)37(1),16–23 (2013).
CASGoogle Scholar
77 de Benedictis FM, Bush A. Corticosteroids in respiratory diseases in children. Am. J. Respir. Crit. Care Med.185(1),12–23 (2012).
Medline CASGoogle Scholar
78 Brun-Buisson C, Richard JC, Mercat A, Thiebaut AC, Brochard L. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med.183(9),1200–1206 (2011).
MedlineGoogle Scholar
79 Kim SH, Hong SB, Yun SC et al. Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. Am. J. Respir. Crit. Care Med.183(9),1207–1214 (2011).
MedlineGoogle Scholar
80 Martin-Loeches I, Lisboa T, Rhodes A et al. Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection. Intensive Care Med.37(2),272–283 (2011).
Medline CASGoogle Scholar
81 Ranzani OT, Ferrer M, Esperatti M et al. Association between systemic corticosteroids and outcomes of intensive care unit-acquired pneumonia. Crit. Care Med.40(9),2552–2561 (2012).
Medline CASGoogle Scholar
82 Eyers S, Weatherall M, Shirtcliffe P, Perrin K, Beasley R. The effect on mortality of antipyretics in the treatment of influenza infection: systematic review and meta-analysis. J. R. Soc. Med.103(10),403–411 (2010).
MedlineGoogle Scholar
83 Sullivan JE, Farrar HC. Fever and antipyretic use in children. Pediatrics127(3),580–587 (2011).
MedlineGoogle Scholar
84 InFACT: a global critical care research response to H1N1. Lancet375(9708),11–13 (2010).
MedlineGoogle Scholar
85 Dellinger RP, Levy MM, Rhodes A et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit. Care Med.41(2),580–637 (2013).
MedlineGoogle Scholar
86 Brooks WA. A four-stage strategy to reduce childhood pneumonia-related mortality by 2015 and beyond. Vaccine27(5),619–623 (2009).▪▪ Perspectives on a comprehensive strategy to address the burden of childhood pneumonia, including those of viral origin.
MedlineGoogle Scholar
87 Aiello AE, Coulborn RM, Aragon TJ et al. Research findings from nonpharmaceutical intervention studies for pandemic influenza and current gaps in the research. Am. J. Infect. Control38(4),251–258 (2010).
MedlineGoogle Scholar
88 Copeland DL, Basurto-Davila R, Chung W et al. Effectiveness of a school district closure for pandemic influenza A (H1N1) on acute respiratory illnesses in the community: a natural experiment. Clin. Infect. Dis.56(4),509–516 (2013).
MedlineGoogle Scholar
89 Nair H, Brooks WA, Katz M et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet378(9807),1917–1930 (2011).
MedlineGoogle Scholar
90 Nair H, Nokes DJ, Gessner BD et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet375(9725),1545–1555 (2010).
MedlineGoogle Scholar
91 O’Brien KL, Wolfson LJ, Watt JP et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet374(9693),893–902 (2009).
MedlineGoogle Scholar
92 Watt JP, Wolfson LJ, O’Brien KL et al. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet374(9693),903–911 (2009).
MedlineGoogle Scholar
101 WHO Disease Outbreak News (2013). www.who.int/csr/don/archive/disease/coronavirus_infections/en/index.html
Google Scholar
102 WHO Disease Outbreak News. www.who.int/csr/don/en
Google Scholar
103 WHO Public Health Research Agenda on Influenza. www.who.int/influenza/resources/research/en/index.html
Google Scholar
104 WHO meeting on development and clinical trials on influenza vaccines that induce broadly protective and long-lasting immune responses 2013. www.who.int/vaccine_research/meetings/fluvaccines_devclinicaltrials_jan13/en/index.html
Google Scholar
105 WHO Battle against Respiratory Viruses (BRaVe) Initiative. www.who.int/influenza/patient_care/clinical/brave/en/index.html
Google Scholar
106 Meeting report for the WHO informal technical consultation ‘Research needs for the Battle against Respiratory Viruses’. www.who.int/influenza/patient_care/clinical/BRaVE_meeting_report_november2012.pdf
Google Scholar
107 BRaVe Call to Action. www.who.int/influenza/patient_care/clinical/call_to_action/en/index.html
Google Scholar
108 BRaVe Research Agenda. www.who.int/influenza/patient_care/clinical/BRaVe_Research_Agenda_2013.pdf
Google Scholar
109 Pneumonia Etiology Research for Child Health (PERCH) study details 2012. www.jhsph.edu/research/centers-and-institutes/ivac/projects/perch/perch-study-details.html
Google Scholar
110 Global Approach for Biological Research on Infectious Epidemics in Low income countries (GABRIEL) pilot study 2011. http://globe-network.org/sites/default/files/documents/public/gabriel/research-projects/pneumonia-multi-centric-pilot-study-project-sheet.pdf
Google Scholar
111 Mechanisms Of Severe Acute Influenza Consortium (MOSAIC) 2011. www1.imperial.ac.uk/medicine/about/institutes/centre_respiratory_infection/mosaic
Google Scholar
112 Synairgen press release 2012. www.synairgen.com/media/1536/19%20april%202012%20Phase%20II%20press%20release%20final.pdf
Google Scholar
113 Biota press release 2012. www.biotapharma.com/uploaded/154/1021819_20hrvphaseiibstudyachieve.pdf
Google Scholar
114 WHO Essential Medicines List. www.who.int/selection_medicines/en
Google Scholar
115 WHO Prequalification Program. http://apps.who.int/prequal
Google Scholar
116 International Forum for Acute Care Trialists (InFACT). www.infactglobal.org
Google Scholar
117 International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). http://isaric.tghn.org
Google Scholar
118 ISARIC post on ProMEDhttp. www.promedmail.org/direct.php?id=20121208.1443486
Google Scholar
119 ISARIC Novel Coronavirus Case Record Form 2013. http://isaric.tghn.org/articles/isaric-novel-coronavirus-crf-version-1
Google Scholar
120 ISARIC and WHO SARI and Natural History Protocols. http://isaric.tghn.org/articles/isaric-and-who-sari-and-natural-history-protocols
Google Scholar
121 WHO Strategic Advisory Group of Experts on immunization (SAGE) position paper 2012. www.who.int/wer/2012/wer8747.pdf
Google Scholar
122 Centers for Disease Control and Prevention, Mortality and Morbidity Weekly Report, 22 February 2013. www.cdc.gov/mmwr
Google Scholar

Vol. 8, No. 10

Metrics

Downloaded 245 times

History

Published online 16 September 2013

Published in print October 2013

Information

Keywords

Acknowledgements

The authors would like to thank D Spiro (NIAID, MD, USA), A Krafft (NIAID, MD, USA) and D Jernigan (US CDC, GA, USA) for their reviews and helpful comments on this article and the BRaVe research agenda.

Financial & competing interests disclosure

WA Brooks has received grant support from Sanofi Pasteur. FG Hayden served as influenza research coordinator from 2008 to 2012 at the Wellcome Trust, London, which provided support to assist WHO in the development of the BRaVe Initiative. Since 2008 FG Hayden has been an unpaid consultant to multiple companies engaged in development and/or marketing of antivirals for influenza and other respiratory viruses. From 2011–2013 both FG Hayden and the University of Virginia have received compensation for his testimony in legal cases involving influenza antivirals. FG Hayden participated as a member of the Neuraminidase Inhibitor Susceptibility Network (NISN), which received support from Roche and GSK; the University of Virginia received honoraria from 2008 to 2011 for his participation in NISN meetings. FG Hayden recently agreed to serve on an independent Data Safety and Monitoring Board for a Sanofi Pasteur influenza vaccine clinical trial with honoraria paid to the University of Virginia. MD de Jong has received consultancy fees for scientific advice relating to antiviral strategies from AIMM Therapeutics, Crucell BV and AVI BioPharma Inc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download